Oncology

Mutant Vaccinia Virus Attacks Tumor Targets, Ignores Resting Cells

Published in Cancer Weekly, January 29th, 2002

by Sonia Nichols, senior medical writer - U.S. government investigators at the National Institutes of Health say they have enhanced the tumor specificity of vaccinia virus in order to increase its effectiveness as an oncolytic agent and gene therapy vector.

The resulting construct, a mutant vaccinia virus devoid of thymidine kinase (TK^-) and vaccinia growth factor (VGF^-), could be used for therapies targeting rapidly dividing cells, a hallmark of tumor progression.

According to J. A. McCart and coinvestigators in the Surgery Branch at the NIH, they inserted enhanced green fluorescent protein into the viral construct, "creating...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2002-01-29)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry